Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Clinical trial NCT04204941 · TERMINATED
Trial details
- NCT number
- NCT04204941
- Sponsor
- Epizyme, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-19
- Primary completion
- 2024-06-14
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.